The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has announced a conference on the development of a clinical research agenda for fecal incontinence (FI).
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has announced that on August 19 – 20, 2013 they will be holding a conference on the development of a clinical research agenda for fecal incontinence (FI). The conference will be held at the Lister Hill Auditorium, Building 38A, NIH Campus in Bethesda, MD.
The conference agenda will cover the following topics;
Epidemiology of Fecal Incontinence (FI)
Etiology, Quantification, and Classification of FI
Review of past FI treatment studies (successes and deficiencies in research)
Strategies for future treatment studies FI
Where we go from here
Dr. Frank Hamilton
The NIDDK supports medical research and medical professional training in the fields of endocrine and metabolic diseases, digestive diseases, nutritional disorders and obesity, and kidney, urologic, and hematologic diseases in the goal of improving patient’s quality of life and overall health. The NIDDK originated in 1950 under President Harry S. Truman and was originally called the National Institute of Arthritis and Metabolic Diseases (NIAMD). In 1986, it was renamed to it’s current designation.
Important Contributions from the NIDDK
- 1973 – The NIDDK is responsible for the creation of the first Diabetes-Endocrinology Research Center.
- 1984 – Grants totaling more than $4 million were awarded to six institutions to establish the Silvio O. Conte Digestive Diseases Research Centers. The research centers investigate the underlying causes, diagnoses, treatments, and prevention of digestive diseases.
- 2000 – The NIDDK initiated the Office of Minority Health Research Coordination to reduce the burden of diseases in the minority population.
- 2009 – President Barack Obama signed the American Recovery and Reinvestment Act (ARRA) of 2009 (P.L. 111-5), providing the NIH with a two-year infusion of funding. The NIDDK developed a plan to use its portion of the ARRA funds to meet the stimulus goals set forth in the Recovery Act. This funding supported a range of biomedical research efforts across the Institute’s research mission.